ProCE Banner Activity

Epcoritamab, a CD3 x CD20 Bispecific Antibody, Plus R2 in R/R Follicular Lymphoma: Updated Analysis of Phase I/II EPCORE NHL-2 Trial

Slideset Download
Conference Coverage
In this updated analysis of the cohort with relapsed/refractory follicular lymphoma enrolled on an ongoing phase I/II trial, epcoritamab in combination with rituximab and lenalidomide was associated with a manageable safety profile and an ORR of 100%.

Released: June 16, 2022

Expiration: June 15, 2023

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

GlaxoSmithKline

Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen

Seagen and Genmab